Trial Profile
Comparing effectiveness and safety of adalimumab and infliximab in biologic-naive patients with Crohn's disease -a population-based Danish real life cohort study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Jan 2018
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Infliximab (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; Therapeutic Use
- 04 Jan 2018 New trial record
- 14 Dec 2017 Primary endpoint has not been met. (Effectiveness outcomes) as per results published in the Alimentary Pharmacology and Therapeutics
- 14 Dec 2017 Results published in the Alimentary Pharmacology and Therapeutics